MedDataX Logo

Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles

NCT ID: NCT02159261

Last Updated: 2017-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-15

Study Completion Date

2016-08-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Local prospective multicenter non-comparative non-interventional observational study. It's planed to assess satisfaction of patients and physicians with results of Yaz Plus treatment for 13 cycles in real practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Oral Contraceptive Study

NCT00185484

Contraception
COMPLETED PHASE3

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164

Contraception Ovulation Inhibition Contraceptives, Oral
COMPLETED PHASE3

YAZ, Oral Contraceptive Registration in China

NCT00819312

Contraception
COMPLETED PHASE3

Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles

NCT00266032

Contraception
COMPLETED PHASE3

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

NCT01254292

Contraception
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-interventional, Yaz Plus, Contraception, Assess satisfaction, Russian Federation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contraception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Female patients ≥ 18 years old requiring contraception.

BAY98-7071_EE20/DRSP/L-5-MTHF

Intervention Type DRUG

Patients treated by Physicians under approved local prescriptions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BAY98-7071_EE20/DRSP/L-5-MTHF

Patients treated by Physicians under approved local prescriptions

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patients ≥ 18 years old
* Requiring contraception
* Prescribed with Yaz Plus for the first time

Exclusion Criteria

* Contraindications for the use of Yaz Plus in accordance with the local product information
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YZ1410RU

Identifier Type: OTHER

Identifier Source: secondary_id

17177

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function
NCT01257984 COMPLETED PHASE3
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
NCT05934942 TERMINATED PHASE1
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
NCT02710708 COMPLETED PHASE4
Yasmin Post Marketing Surveillance
NCT00923572 COMPLETED
Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.
NCT00367276 COMPLETED PHASE3
To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea
NCT02617537 WITHDRAWN PHASE3
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
NCT00905684 COMPLETED
Non-interventional, Real Life Study on Satisfaction With LNG-IUS in Spanish Young Women (18-30 Years Old) With Different Parity Status and Menstrual Bleeding Pattern
NCT03493295 COMPLETED
SH T00186 in the Treatment of Primary Dysmenorrhea
NCT00569244 COMPLETED PHASE3
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
NCT00631124 COMPLETED PHASE2
Data on Oral Contraceptives Compliance in Non Stop Regimen
NCT01185678 COMPLETED
KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method
NCT03182140 COMPLETED
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
NCT00824187 COMPLETED PHASE3
Regulatory Post Marketing Surveillance Study on YAZ
NCT00998257 COMPLETED
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
NCT00651469 COMPLETED PHASE3
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.
NCT01182194 COMPLETED PHASE1
Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being
NCT00988910 COMPLETED
Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects
NCT02159131 COMPLETED PHASE1
Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®
NCT06233071 RECRUITING PHASE1
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
NCT00722761 COMPLETED PHASE3
Study to Investigate Efficacy and Safety of a New Oral Contraceptive
NCT00185289 COMPLETED PHASE3
Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive
NCT00362479 COMPLETED PHASE3
Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®
NCT06233058 NOT_YET_RECRUITING PHASE1
A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
NCT01195974 TERMINATED PHASE1
GA YAZ ACNE in China Phase III
NCT00818519 COMPLETED PHASE3